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In situ Delivery of Tumor Antigen– and
Adjuvant-Loaded Liposomes Boosts Antigen-Speciﬁc
T-Cell Responses by Human Dermal Dendritic Cells
Martine A. Boks1, Sven C.M. Bruijns1, Martino Ambrosini1, Hakan Kalay1, Louis van Bloois2, Gert Storm2,3,
Tanja de Gruijl4 and Yvette van Kooyk1
Dendritic cells (DCs) have an important role in tumor control via the induction of tumor-speciﬁc T-cell responses
and are therefore an ideal target for immunotherapy. The human skin is an attractive site for tumor vaccination as
it contains various DC subsets. The simultaneous delivery of tumor antigen with an adjuvant is beneﬁcial for
cross-presentation and the induction of tumor-speciﬁc T-cell responses. We therefore developed liposomes that
contain the melanoma-associated antigen glycoprotein 100280-288 peptide and Toll-like receptor 4 (TLR4) ligand
monophosphoryl lipid A (MPLA) as adjuvant. These liposomes are efﬁciently taken up by monocyte-derived DCs,
and antigen presentation to CD8+ T cells was signiﬁcantly higher with MPLA-modiﬁed liposomes as compared
with non-modiﬁed liposomes or the co-administration of soluble MPLA. We used a human skin explant model to
evaluate the efﬁciency of intradermal delivery of liposomes. Liposomes were efﬁciently taken up by CD1a+ and
especially CD14+ dermal DCs. Induction of CD8+ T–cell responses by emigrated dermal DCs was signiﬁcantly
higher when MPLA was incorporated into the liposomes as compared with non-modiﬁed liposomes or co-
administration of soluble MPLA. Thus, the modiﬁcation of antigen-carrying liposomes with TLR ligand MPLA
signiﬁcantly enhances tumor-speciﬁc T-cell responses by dermal DCs and is an attractive vaccination strategy in
human skin.
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INTRODUCTION
Dendritic cells (DCs) are professional antigen-presenting cells
(APCs) capable of initiating adaptive immune responses
(Banchereau et al., 2000). Immature DCs are sentinel cells
located in peripheral tissues, such as mucosa and the skin,
and in blood and lymphoid organs. Immature DCs express
many pattern recognition receptors, for example Toll-like
receptors (TLRs), and internalization receptors, which enables
them to recognize and internalize pathogens (Janeway and
Medzhitov, 2002; Kawai and Akira, 2010). This is followed by
a maturation process and migration to draining lymph nodes
where naive T cells reside. Concurrently, internalized antigen
is processed and loaded onto major histocompatibility
complex (MHC) class I and II molecules for presentation to
CD8+ and CD4+ T cells, respectively (Jensen, 2007).
Exogenous antigens are internalized and shuttled to the
endo-lysosomal pathway for presentation in MHC class II
molecules. However, exogenous antigens can also be
presented in MHC class I molecules via a process called
“cross-presentation” (Carbone and Bevan, 1990; Joffre et al.,
2012). Antigen presentation in MHC class I molecules is
important for the induction of CD8+ cytotoxic effector T
lymphocytes (CTLs), which are essential for clearing the
pathogen-infected cells and tumor cells (Appay et al., 2008).
The skin is an immunologically active tissue that harbors
various APC subsets, such as Langerhans cells (LCs) in the
epidermis, and macrophages and various DC subsets in the
dermis. Human LCs efﬁciently induce CD4+ and CD8+ T–cell
responses but in resting state also induce regulatory T cells,
thereby maintaining skin homeostasis (Klechevsky et al.,
2008; Seneschal et al., 2012). The main populations of dermal
DCs (dDCs) that can be found in the human skin are CD1a+
DCs and CD14+ DCs. CD1a+ dDCs are found in the human
skin–draining lymph nodes and therefore considered
migratory DCs, which have potent T-cell stimulating capa-
cities (Nestle et al., 1993; van de Ven et al., 2011; Segura
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et al., 2012). CD14+ dDCs have a role in humoral responses
but showed a poor ability to stimulate naive CD4+ and CD8+
T–cell proliferation, as well as a poor ability to migrate to the
lymph nodes, and are therefore recently proposed as a
macrophage-like cell subset (Nestle et al., 1993; Klechevsky
et al., 2008; Matthews et al., 2012; McGovern et al., 2014).
With various DC subsets, the human skin is an attractive
and an easily accessible site for antigen-based vaccination.
Delivery of antigen to dDCs in situ enhances antigen cross-
presentation and CTL responses (Schneider et al., 2012;
Fehres et al., 2013; Oosterhoff et al., 2013). The simultaneous
delivery of antigen together with a potent adjuvant, such as
TLR ligands, will enhance the cross-presentation capacity of
DCs and the generation of T-cell responses (Joffre et al.,
2012). Liposomes are spherical particles that consist of phos-
pholipid bilayers that are ideal as delivery vehicles, as large
amounts of hydrophilic and hydrophobic molecules can be
encapsulated, and may serve as antigen reservoir prolonging
MHC class I antigen presentation (Torchilin, 2005; Joshi et al.,
2012). Using liposomes offers the opportunity to include
various tumor antigens, as well as different types of DC-
activating molecules––for example, TLR agonists. Liposomes
have low toxicity and are well tolerated by the body because
of their assembly with naturally derived compounds.
Our aim is to develop a therapy using liposomes for the
simultaneous delivery of tumor antigen and adjuvant to
human skin–resident DCs. We used a human skin explant
model to evaluate DC function in the natural complex tissue
environment and to explore the potential of intradermally
delivered vaccine. We generated liposomes with a
melanoma-associated peptide derived from glycoprotein
100 (gp100) protein together with the TLR4 ligand monopho-
sphoryl lipid A (MPLA), which easily incorporates into the
lipid bilayer of liposomes. MPLA is a detoxiﬁed, but still
immunostimulatory, derivative of lipopolysaccharide that has
been shown effective in different studies as vaccines to
malaria, HIV, and several types of cancer (Steinhagen et al.,
2011). Incorporation of MPLA into liposomes resulted in
efﬁcient DC maturation and enhanced tumor antigen cross-
presentation to gp100-speciﬁc CD8+ T cells. Importantly,
cross-presentation was only enhanced when MPLA was
incorporated in the liposomes, as soluble MPLA did not
affect cross-presentation. Our data demonstrate the effective
delivery of tumor antigen and TLR ligand via liposomes to
dDCs and the potency as anti-cancer vaccine for stimulating
the skin APCs to instruct tumor-speciﬁc CD8+ T–cell
responses.
RESULTS
MPLA-modiﬁed liposomes are taken up by human monocyte–
derived DCs and induce maturation and cytokine production
As a carrier for tumor antigen and adjuvant, we prepared
liposomes on a phosphatidylcholine, phosphatidylglycerol,
and cholesterol basis as described in Materials and Methods
section. The size, the polydispersity index, zeta potential,
phospholipid concentration, and the amount of encapsulated
ﬂuorochrome DiD were determined (Table 1) as previously
described (Joshi et al., 2011). The amount of liposomes (total
lipid) used in the experiments was calculated based on the
determined phospholipid contents. The ﬂuorochrome DiD
was incorporated for research purposes. We incorporated an
MHC class I-restricted gp100280-288 melanoma-associated
peptide for presentation by HLA-A2+ DC to gp100-speciﬁc
T cells. Furthermore, we incorporated the TLR4 agonist
MPLA, a derivative of Salmonella Minnesota lipopolysacchar-
ide, which as a lipid easily incorporates into the lipid bilayer
of the liposomes. The purpose of TLR ligand incorporation
into liposomes is to enhance the adjuvanticity of the
liposomes and to increase vaccine efﬁcacy in inducing T-cell
responses.
DCs are phagocytic cells that efﬁciently take up (particu-
late) antigens from their surroundings. We ﬁrst assessed
whether human DCs take up these MPLA-loaded liposomes.
Incubation of monocyte-derived DCs (moDCs) with non-
modiﬁed or MPLA-containing liposomes resulted both in
highly efﬁcient dose-dependent uptake of the liposomes
(Figures 1a and b). As expected, incorporation of MPLA did
not signiﬁcantly interfere with the uptake of liposomes by
DCs. Next, we analyzed the effect of MPLA-modiﬁed
liposomes on moDC maturation and cytokine production.
MPLA incorporation into liposomes showed a tendency to
induce the expression of maturation marker CD83 and
costimulatory molecule CD86 (Figure 1c). Also, production
of pro-inﬂammatory cytokines TNF-α and IL-6 seemed to be
induced by MPLA-modiﬁed liposomes (Figure 1d). Although
not signiﬁcantly different because of donor variations in the
expression and production levels, we observed upregulation
of CD83, CD86, TNF-α, and IL-6 in every donor when treated
with MPLA-modiﬁed liposomes. Importantly, DC activation
was evident both after treatment with liposomal MPLA and
soluble MPLA, albeit at slightly lower levels for liposomal
MPLA. These data show that modiﬁcation of liposomal
carriers with adjuvant MPLA results in effective DC matura-
tion and cytokine production.
Table 1. Physical characteristics of liposome formulations
Mean size (nm) Polydispersity index Zeta potential (mV) Concentration (mM) DiD (MFI)1
Empty 214±16 0.06±0.02 − 52.0±6.3 6.5±0.5 58.6±10.8
MPLA 210±14 0.05±0.03 − 52.7±7.4 7.5±1.1 53.0±1.0
Abbreviations: MFI, mean ﬂuorescence intensity; MPLA, monophosphoryl lipid A.
Data of seven liposome batches represented as mean± SD.
1MFI measured by ﬂow cytometry.
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Administration of MPLA-modiﬁed liposomes, but not soluble
MPLA, enhances antigen presentation to CD8+ T cells
The uptake of liposomes and subsequent activation of DCs
may facilitate antigen cross-presentation to CD8+ T cells. In
contrast to soluble short peptide that will directly load onto
MHC molecules, liposomal short peptides will be taken up
by DCs and enter the cross-presentation route. TLR ligand–
modiﬁed liposomes containing an MHC class I-restricted
gp100280-288 peptide were incubated with HLA-A2
+ moDC.
Subsequently, DCs were co-cultured with a gp100-speciﬁc
CD8+ T–cell clone. Loading of DCs with liposomes that
contain MPLA markedly enhanced presentation of the gp100
peptide to CD8+ T cells as revealed by signiﬁcantly higher IFN-
γ production, even at lower liposome concentrations (Figure 2).
We observed no IFN-γ production without administration
of the gp100 peptide (data not shown), indicating that the
production of IFN-γ is tumor antigen speciﬁc. Administration of
soluble MPLA together with gp100-containing liposomes did
not enhance T-cell IFNγ production. These results demonstrate
that simultaneous administration of tumor antigen and
adjuvant, incorporated into the same particle, to DC increases
cross-presentation to CD8+ T cells.
MPLA-modiﬁed liposomes are taken up by human dermal DCs
after intradermal injection
Next, we investigated whether MPLA-modiﬁed liposomes are
internalized by dDCs in situ in a human skin explant model.
Two days after intradermal injection of liposomes, dDCs
emigrated from skin biopsies were collected, and liposome
internalization was studied. Figure 3a shows our gating strategy
for CD1a+ and CD14+ dDC. Total (HLA-DR+) dDCs were
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Figure 1. Monophosphoryl lipid A (MPLA)-modiﬁed liposomes are taken up by human monocyte–derived dendritic cells (DCs) and induce DC maturation and
cytokine production. Human monocyte-derived DCs (moDCs) were exposed to various concentrations of non-modiﬁed or MPLA-modiﬁed liposomes for 3 hours
at 37 °C and analyzed by ﬂow cytometry. (a) Histograms of liposome uptake. Tinted gray: DC only; solid lines: DC with liposomes. (b) Data are shown as
mean± SEM of six independent experiments. (c and d) moDCs were stimulated with liposomes (100 nmol) or soluble MPLA (concentration as used for liposome
preparation) overnight at 37 °C. DCs were analyzed by ﬂow cytometry for maturation, (c) or cytokine production was measured in culture supernatants by
ELISA (d). Data are shown as mean± SEM of duplicate cultures of 4 independent experiments. MFI, mean ﬂuorescence intensity.
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Figure 2. Liposome-incorporated monophosphoryl lipid A (MPLA) enhances
antigen presentation by dendritic cells (DCs) to CD8+ T cells. HLA-A2+
monocyte-derived DCs (moDCs) were exposed to various concentrations of
non-modiﬁed or MPLA-modiﬁed liposomes loaded with gp100280-288 peptide
for 1 hour. Non-modiﬁed liposomes were used in the presence or absence of
soluble MPLA. After extensive washing, an HLA-A2-restricted gp100-speciﬁc
CD8+ T–cell clone was added, and after 24 hours supernatants were taken and
analyzed for IFN-γ production by ELISA. Data are shown as mean± SEM of
triplicate cultures. Results are representative of three independent
experiments. **P⩽ 0.01 and ***P⩽0.001 signiﬁcant difference to
non-modiﬁed gp100 liposomes. NS, not signiﬁcant.
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shown to efﬁciently take up liposomes (Figure 3b). Inclusion of
MPLA in the lipid bilayer of the liposomes did not signiﬁcantly
alter the uptake. Moreover, analysis of liposome internalization
by the CD14+ and CD1a+ dDC subsets showed that CD14+
DCs had taken up a higher amount of liposomes on a per cell
basis (Figure 3c). Further analysis of the percentage of emigrated
DC subsets revealed that it was, however, primarily the CD1a+
DC subset that migrated out of the skin (Figure 3d), with no
difference between TLR-stimulated or non-stimulated condi-
tions. Thus, dDCs are capable of taking up TLR ligand–modiﬁed
liposomes and migrate out of the skin.
Injection of MPLA-modiﬁed liposomes, but not soluble MPLA,
induces pro-inﬂammatory cytokine production
We investigated the potential of intradermally injected TLR
ligand–modiﬁed liposomes to activate dDCs. Both CD14+ and
CD1a+ dDC subsets express TLR4, the receptor for MPLA
(Figure 4a), as shown previously (van der Aar et al., 2007;
Harman et al., 2013). Two days after injection, biopsy culture
supernatants were collected and investigated for cytokine
production. Injection of MPLA-modiﬁed liposomes in the skin
showed a tendency to enhance the production of pro-
inﬂammatory cytokines IL-6, IL-8, and IL-1β (Figure 4b). Impor-
tantly, this enhancement of cytokine production was not seen
when soluble MPLA was injected into the skin, in keeping with
our previous observations (Oosterhoff et al., 2013; Fehres et al.,
2014). These results suggest that the administration of liposomal
MPLA, but not soluble MPLA, enhances the production of pro-
inﬂammatory cytokines in the skin microenvironment.
Intradermal delivery of MPLA-modiﬁed liposomes enhances
antigen presentation by dermal DCs
As MPLA-modiﬁed liposomes are efﬁciently taken up by
dDCs and induce the production of pro-inﬂammatory
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Figure 3. In situ liposome uptake and emigration of dermal dendritic cell (DC) subsets. Liposomes (50 nmol; b–d), medium (a, b and d) or soluble
monophosphoryl lipid A (MPLA) (d), were injected intradermally. Biopsies were taken and after 2 days of culture dermal DCs (dDCs) were collected and
stained for HLA-DR and dDC subset markers CD1a and CD14 and analyzed for liposome uptake. (a) Gating strategy after cell migration out of skin biopsies.
(b) Dotplots of liposome internalization by total HLA-DR+ dDC. Representative of three experiments is shown. Data are shown as mean± SEM of three (c) or
two (d) independent experiments. MFI, mean ﬂuorescence intensity.
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cytokines, we examined the effect of liposomal MPLA on
antigen cross-presentation of a liposome-incorporated
gp100280-288 peptide by dDCs. Liposomes were injected
intradermally into the skin of an HLA-A2+ donor, and after
2 days emigrated dDCs were collected and co-cultured with a
gp100-speciﬁc HLA-A2-restricted CD8+ T–cell clone. Incor-
poration of MPLA into liposomes enhanced antigen presenta-
tion by dDCs, as measured by increased IFN-γ production by
the T cells (Figure 5). Of note, co-administration of soluble
MPLA with gp100-containing liposomes did not enhance
antigen presentation, indicating that antigen and adjuvant
need to be present in the same formulation to allow most
efﬁcient antigen presentation of skin APCs. These results
demonstrate that simultaneous delivery of tumor antigen and
the adjuvant MPLA to dDC augments antigen cross-
presentation to CD8+ T cells.
DISCUSSION
Here we evaluated a two-component vaccine strategy in a
human skin explant model for induction of cross-presentation
by dDCs. The incorporation of the clinically applicable TLR4
ligand MPLA into liposomes resulted in enhanced DC
maturation and cytokine production. Moreover, the uptake
of MPLA-containing liposomes induced efﬁcient presentation
of the gp100280-288 peptide to CD8
+ T cells by dDCs.
Importantly, presentation was only enhanced upon simulta-
neous delivery of tumor antigen and adjuvant, whereas co-
administration of soluble MPLA with liposome-encapsulated
tumor antigen did not enhance cross-presentation.
The skin is an attractive immunological target for vaccina-
tion purposes, because of its relatively high content of APC. In
our study, intradermal vaccination of antigen and adjuvant is
mimicked ex vivo by using skin explants from healthy donors
that underwent corrective plastic surgery. In this model, DC
function can be studied in their natural complex tissue
environment and is a highly representative model of the
in vivo situation (Fehres et al., 2013; Oosterhoff et al., 2013).
We here show that intradermal vaccination with tumor
antigen– and adjuvant-containing liposomes results in the
uptake of liposomes by dDCs. Especially, the CD14+ dDC
subset showed high phagocytic capacity, but it was mainly
the CD1a+ dDC subset that migrated out of the skin. CD14+
dDCs may therefore be important at inducing T-cell responses
locally in the skin. Indeed, it was shown that inﬂammatory
DCs may shape adaptive immunity in situ by activating tissue-
resident effector memory CD8+ T cells, thereby showing that
a T-cell response mechanism in extra-lymphoid tissues can
act to control localized infection (Wakim et al., 2008). For
CD14+ dermal cells, it was shown that they efﬁciently
activate memory T–cell responses (Klechevsky et al., 2008;
McGovern et al., 2014). Thus, the uptake of therapeutic
liposomes by both the resident CD14+ dermal cells and the
migratory CD1a+ subset might be beneﬁcial for inducing
primary T-cell responses in skin-draining lymph nodes as well
as activating memory T cells locally in the skin.
Generally, the maturation of DCs enhances the efﬁcacy to
cross-present antigen. A large number of TLR ligands act as
adjuvants and thereby augment cross-presentation (Nair-
Gupta et al., 2014). However, administration of soluble TLR
ligands in the dermis does not induce maturation of dDCs as
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Figure 4. Increased production of pro-inﬂammatory cytokines after
intradermal injection with monophosphoryl lipid A (MPLA)-modiﬁed
liposomes. (a) Toll-like receptor 4 (TLR4) expression by emigrated CD1a+ and
CD14+ dDCs. Intracellular staining of dermal dendritic cells (dDCs) after 2-day
spontaneous migration out of skin biopsies. Tinted gray: isotype controls; solid
lines: TLR4 staining. (b) Liposomes (50 nmol) or soluble MPLA was injected
intradermally. After 2 days of skin biopsy culture, supernatants were collected,
and cytokine production was measured by ELISA. Data are shown as
mean± SEM of three or two (IL-1β) independent experiments.
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Figure 5. Liposome-incorporated monophosphoryl lipid A (MPLA) enhances
antigen presentation by dermal dendritic cells (DCs) to CD8+ T cells after
intradermal injection in human skin. Various concentrations of non-modiﬁed
or MPLA-modiﬁed liposomes loaded with gp100280-288 peptide were
injected intradermally in HLA-A2+ skin. Non-modiﬁed liposomes were also
co-injected with soluble MPLA. Emigrated dendritic cells (DCs) were collected
after 2 days of skin biopsy culture. Emigrated dDCs were co-cultured with
an HLA-A2-restricted gp100-speciﬁc CD8+ T–cell clone. After 24 hours,
supernatants were taken and analyzed for IFN-γ production by ELISA. Data are
shown as mean± SEM of duplicate cultures. Results are representative of
three independent experiments.
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seen with in vitro-generated moDC, except for modest effects
of MPLA, Poly I:C, and several combinations of TLR ligands
(Schneider et al., 2012; Oosterhoff et al., 2013; Fehres et al.,
2014). Using liposomal carriers gives the opportunity to co-
deliver adjuvants along with antigens to enhance maturation
and cross-presentation of the DCs. A study by Schlosser et al.
(2008), demonstrated that in vivo cross-priming and CTL
responses were enhanced when an antigen, i.e., OVA, was
co-encapsulated together with an adjuvant, CpG or Poly I:C,
in biodegradable nanoparticles, as compared with inocula-
tion of antigen-containing nanoparticles with soluble adju-
vant or separately encapsulated adjuvant. Therefore, we used
liposomes to simultaneously deliver tumor antigen and
adjuvant to DCs in situ. Our data show that in vitro activation
of moDC was similar for liposomal and soluble MPLA ligands.
However, cross-presentation was enhanced with co-delivery
of MPLA and antigen in liposomes. Remarkably, cross-
presentation was enhanced even at low concentrations of
gp100/MPLA liposomes. It is possible that the delivery of
antigen and the triggering of TLR4, both on the cell surface,
as well as intracellular, on the same cell result in superior
antigen presentation to T cells. This in contrast to gp100
liposomes administered with soluble MPLA, where MPLA
predominantly triggers cell-surface TLR4, possibly resulting in
a different effect on the antigen presentation route. Further-
more, it is not assured that the liposomes and MPLA given
soluble reach the same cell for simultaneous TLR4 triggering
and antigen presentation. Also cross-presentation by dDCs
after intradermal injection of liposomes containing both tumor
antigen and MPLA was enhanced compared with injection of
soluble MPLA, demonstrating the necessity of co-delivery of
antigen and adjuvant in one particulate formulation.
The potency of liposomal delivery of tumor antigen and
TLR ligand in the skin was shown in an in vivo study by
Jerome et al. (2006), where they used a melanoma peptide
tyrosinase–related protein 2 in combination with CpG as
adjuvant. After intradermal prime-boost vaccination, reactive
CTL populations were generated even against poorly immu-
nogenic tumors, resulting in a potent anti-tumour immune
response in vivo. The authors observed a reduction in tumor
volume and prolonged survival times upon prophylactic
vaccination with low-dose TPR2-encapsulated liposomes
with CpG compared with untreated animals or free peptide-
treated mice. Although the results with CpG delivery are very
promising for determining vaccination strategies, it might not
be the best human adjuvant for skin vaccination as TLR9 is
not expressed on human myeloid skin APCs as it is a ligand
for TLR9, which is only expressed by plasmacytoid DCs.
Concluding, the uptake of liposomal antigens and the
simultaneous DC activation by liposomal MPLA resulted in
enhanced tumor antigen cross-presentation to CD8+ T cells
by moDC and dDCs. Our data demonstrate the effective
delivery of liposomes in situ to dDCs and the potency as anti-
tumor vaccine for inducing tumor-speciﬁc T-cell responses.
Future research is needed to investigate whether liposomal
vaccination could also induce de novo tumor-speciﬁc T-cell
responses from primary naive T cells. We propose that
liposomes can be used to deliver tumor antigen and adjuvants
directly to dDCs in vivo and can be exploited as a vaccine
platform to induce potent anti-tumor immune responses.
MATERIALS AND METHODS
Liposome preparation and MPLA and peptide incorporation
Liposomes containing TLR ligands were prepared from a mixture of
phospholipids and cholesterol, utilizing the ﬁlm extrusion method as
described previously (Joshi et al., 2011). Brieﬂy, EPC-35 (Lipoid,
Ludwigshafen, Germany):EPG-Na (Lipoid):cholesterol (Sigma-
Aldrich, St Louis, MO) at a molar ratio of 3.8:1:2.5 in mol were
dissolved in a mixture of chloroform/methanol. Overall, 0.1% in mol
of the lipophilic ﬂuorescent tracer DiD (1′-dioctadecyl-3,3,3′,3′-
tetramethyl indodicarbocyanine; Life Technologies, Bleiswijk, The
Netherlands) was added to the mixture and, where speciﬁed, MPLA
(2% mol; Invivogen, Toulouse, France) was added. A lipid ﬁlm was
obtained by evaporation of the solvent under reduced pressure at
50 °C that was hydrated in HEPES buffer solution pH 7.5 containing
the antigenic peptide gp100280-288 (YLEPGPVTA), yielding a lipo-
some preparation of 14.6 μmol total lipid ml−1. The peptide was
produced by solid-phase peptide synthesis using Fmoc-chemistry
with a Symphony peptide synthesizer (Protein Technologies, Tucson,
AZ). After extrusion through two stacked polycarbonate ﬁlters of
200 nm, the non-encapsulated peptides were washed away by two
consecutive ultracentrifugations on Beckman Ultracentrifuge at
55,000 r.p.m. The ﬁnal suspension of liposomes was made in Hepes
buffer pH 7.5. The concentration of encapsulated gp100 peptide was
quantiﬁed by HPLC after extraction with 1 v/v of water, 1 v/v of
MeOH, and 2 v/v of CHCl3 and was routinely 50 μg ml−1.
MoDC culture
Human immature DCs were generated from monocytes isolated from
buffy coats of healthy donors (Sanquin, Amsterdam, The Netherlands).
Informed consent was obtained from all blood donors for the use of
their blood. Monocytes were isolated by subsequent ﬁcoll gradient
(Lymfoprep; Axis-Shield PoC AS, Oslo, Norway) and percoll gradient
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Monocytes were
cultured for 5–6 days in RPMI1640 medium (Invitrogen, Paisley, UK)
containing 10% fetal calf serum, 50Uml−1 penicillin, 50 μgml−1
streptomycin, and 2mM glutamine (all from Lonza, Verviers, Belgium)
in the presence of r.h.IL-4 and r.h.GM-CSF (500Uml−1 and 800
Uml−1, respectively; Immunotools, Friesoythe, Germany; Romani
et al., 1994; Sallusto and Lanzavecchia, 1994; Gluckman et al., 1997).
Liposome uptake by moDC
Uptake of modiﬁed liposomes (in concentrations as stated) was
analyzed by ﬂow cytometry following incubation with 50,000
moDCs for 3 hours at 37 °C. Uptake was quantiﬁed by FACS
(FACSCalibur, Becton Dickinson, San Jose, CA) and analyzed using
FlowJo Software (Tree Star, Ashland, OR).
moDC maturation and cytokine production by MPLA-modiﬁed
liposomes
A total of 50,000 moDCs were incubated with liposomes (100 nmol)
or equivalent concentrations as used for liposome generation of
MPLA (Sigma-Aldrich) overnight at 37 °C. Supernatants were
collected for cytokine ELISA, and cells were washed and incubated
with monoclonal antibodies (mAb) speciﬁc for CD83 (Beckman
Coulter, Woerden, The Netherlands) or CD86 (Becton Dickinson,
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San Jose, CA) for analysis of maturation status by ﬂow cytometry. The
levels of IL-6 and TNF-α in the cell culture supernatants were
quantiﬁed using standard sandwich ELISA antibody pairs from
Invitrogen following manufacturer's instructions.
Antigen presentation of gp100 peptide to CD8+ T cells
An HLA–A2-restricted CD8+ T–cell clone speciﬁc for gp100280-288
was generated and cultured as described previously (Schaft et al.,
2003). HLA-A2+ DCs were incubated with indicated concentrations of
liposomes in a round bottom 96-well plate for 1 hour at 37 °C. After
extensive washing, DCs were co-cultured with 100,000 gp100-speciﬁc
CD8+ T cells in a 1:3.33 ratio. After overnight incubation, supernatants
were collected, and IFN-γ levels were measured by sandwich ELISA
using speciﬁc antibody pairs from Invitrogen.
Intradermal injection of liposomes, culture of skin biopsies, and
analysis of emigrated skin cells
Human skin explants were derived from abdominal resections
from healthy donors (Bergman Clinics, Bilthoven, The Netherlands)
within 24 hours after surgery. Material was obtained with informed
consent (information leaﬂet for use of ‘left-over’ material), which was
approved by the Medical Ethical Committee of VUmc. Liposomes or
equivalent concentrations of MPLA (Sigma-Aldrich) were diluted in
serum-free Iscove’s modiﬁed Dulbecco's medium (Invitrogen) con-
taining 50 Uml− 1 penicillin, 50 μgml−1 streptomycin, 2 mM gluta-
mine (Lonza) and 10 μg ml−1 gentamycin (Invitrogen), and r.h.IL-4
and r.h.GM-CSF (500 Uml− 1 and 800 Uml−1, respectively;
Immunotools, Friesoythe, Germany) and injected intradermally in a
volume of 20 μl per biopsy (50 nmol or as indicated). Biopsies were
taken immediately after injection using a 6mm biopsy punch
(Microtek Medical Malta, Zutphen, The Netherlands) and cultured
with epidermal side up ﬂoating in a 48-well plate containing 1ml of
IMDM medium supplemented with 10% fetal calf serum, penicillin,
streptomycin, glutamine, and gentamycin at 37 °C. In each experi-
ment, 8 biopsies were taken per experimental condition. After 48
hours of culture, the biopsies were discarded, and emigrated dDCs
were collected and used for experiments. Supernatants of biopsy
cultures were collected and analyzed for cytokine production.
Internaliation of liposomes by emigrated skin cells was analyzed
using ﬂow cytometry. Fluochrome-conjugated mAbs used were
speciﬁc for CD1a, CD14 (Becton Dickinson), and HLA-DR (R&D
Systems, Minneapolis, MN), and biotin-conjugated goat Ab used
speciﬁc for TLR4 or goat IgG Ab as isotype control (R&D Systems)
with donkey anti-goat Alexa 647 (Molecular Probes, Bleiswijk,
The Netherlands). For antigen presentation, emigrated HLA-A2+ skin
cells were collected and co-cultured with 100,000 gp100-speciﬁc
CD8+ T cells in a 5:1 ratio. After overnight incubation, supernatants
were collected, and IFN-γ levels were measured by ELISA.
Statistical analysis
Results were analyzed with one-way or two-way analysis of variance,
followed by the Bonferroni post-test, using GraphPad Prism software
(San Diego, CA; version 5.01). Values were considered to be
signiﬁcantly different when P⩽ 0.05.
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